Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Prescott Atkinson

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Frontiers in Immunology|January 6, 2023
Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig<sup>®</sup>]) in the treatment of patients with primary immunodeficienciesRoger H Kobayashi, Sudhir Gupta, Isaac Melamed, et al.
Journal of Clinical Immunology|September 5, 2015
Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of AgeNiraj C Patel, Joel L Gallagher, Hans D Ochs, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Frontiers in Immunology|January 6, 2023
Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig<sup>®</sup>]) in the treatment of patients with primary immunodeficienciesRoger H Kobayashi, Sudhir Gupta, Isaac Melamed, et al.
Journal of Clinical Immunology|September 5, 2015
Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of AgeNiraj C Patel, Joel L Gallagher, Hans D Ochs, et al.
Pageof 2